A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome.


Neurology. 2003 Nov 11;61(9):1282-4.  

Pritchard J, Gray IA, Idrissova ZR, Lecky BR, Sutton IJ, Swan AV, Willison HJ, Winer JB, Hughes RA.

Department of Clinical Neurosciences, Guy's, King's & St. Thomas' School of Medicine, London, UK.

The authors recruited 19 nonambulant patients with Guillain-Barré syndrome into a pilot, double-blind, randomized, placebo-controlled safety trial of interferon beta 1a (IFN[beta]-1a) (Rebif). Participants received IFN[beta]-1a or placebo subcutaneously three times weekly, 22 microg for the first week and then 44 microg for up to 24 weeks, in addition to IV immunoglobulin (IVIg). IFN[beta] did not have any unexpected interaction with IVIg and there was no significant difference in rate of improvement.

Publication Types:
  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

PMID: 14610140 [PubMed - indexed for MEDLINE]
Copyright © 2018 PPTA. All rights reserved. (202) 789-3100